Investor Relations
Aomics GmbH builds Adaptrials, the Bayesian decision copilot for adaptive clinical trials. This page provides investors, analysts and partners with company, financial and governance information.
Why invest
Bayesian adaptive trials at scale
A single platform that takes a sponsor from prior elicitation to reviewer-ready adaptive design submissions — replacing hand-rolled pipelines that fail inspection.
Traction with the right customers
Emerging biopharma, CROs and clinical biometrics teams who need statistical rigour without enterprise headcount.
Regulatory-grade foundation
Designed with ICH E9(R1), ICH E6(R3), FDA adaptive-design guidance and 21 CFR Part 11 expectations in mind. The local product is a synthetic demonstration; production qualification and sponsor controls remain required.
Corporate governance
Aomics GmbH
Private limited company (GmbH) registered in Germany, Königstein im Taunus.
Registered office
Wiesbadener Str. 120, 61462 Königstein im Taunus, Germany.
Commercial register
Register details available on request from the investor contact.
Reporting
Annual financial statements prepared under German GAAP (HGB) and published on request to qualified investors.
Reports & documents
Company and product documents are available on request from the investor contact below.
Investor contact
For financial reports, ownership questions or partnership enquiries, send a message below or contact our investor relations team directly.
Prefer your own mail client? contact@aomics.com · Aomics GmbH · Wiesbadener Str. 120, 61462 Königstein im Taunus, Germany